Kura Oncology Inc
KURA
查看详细走势图
7.830USD
+0.430+5.81%
收盘 02/06, 16:00（美东）报价延迟15分钟
681.34M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+5.81%
5天
-3.57%
1月
-17.92%
6月
+29.85%
今年开始到现在
-24.64%
1年
-11.22%
查看详细走势图
TradingKey Kura Oncology Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Kura Oncology Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名62/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价32.45。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Kura Oncology Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Kura Oncology Inc亮点
亮点风险
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a FTI, is being evaluated in a Phase I dose-escalation trial as a monotherapy and in combination with targeted therapies.
业绩增长期
公司处于发展阶段，最新年度总收入53.88M美元
利润高增长
公司净利润处于行业前列，最新年度总收入53.88M美元
估值高估
公司最新PE估值-3.17，处于3年历史高位
机构减仓
最新机构持股86.47M股，环比减少24.24%
Hotchkis & Wiley持仓
明星投资者Hotchkis & Wiley持仓，最新持仓市值420.00
活跃度增加
近期活跃度增加，过去20天平均换手率0.53
分析师目标
根据
15
位分析师
买入
评级
32.455
目标均价
+338.57%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Kura Oncology Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Kura Oncology Inc简介
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a FTI, is being evaluated in a Phase I dose-escalation trial as a monotherapy and in combination with targeted therapies.
公司代码KURA
公司Kura Oncology Inc
CEOWilson (Troy E)
网址https://www.kuraoncology.com/
相关品种
